Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, a...
Main Authors: | Pedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2018-12-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs |
Similar Items
-
Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
by: Francesca Sivori, et al.
Published: (2022-04-01) -
Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report
by: Aneta GUZEK, et al.
Published: (2018-01-01) -
Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
by: Petros Ioannou, et al.
Published: (2023-07-01) -
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
by: Nicholas A. Turner, et al.
Published: (2022-05-01) -
In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant <i>Staphylococcus aureus</i> Associated with Skin and Soft Tissue Infections
by: Sofia Maraki, et al.
Published: (2023-05-01)